Harold J. Burstein, MD, PhD, and William J. Gradishar, MD, on ER+ Breast Cancer: Coming Changes in Treatment

Posted: Thursday, March 16, 2017

Harold J. Burstein, MD, PhD, of Harvard Medical School and Dana-Farber Cancer Institute, talks with William J. Gradishar, MD, of the Robert H Lurie Comprehensive Cancer Center, about how SABCS 2016 presentations on CDK 4/6 inhibitors, mTOR inhibitors, and novel tools, such as genomic assays, will likely affect future iterations of the NCCN Guidelines for Breast Cancer.